4.8 Article

Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis

Journal

NATURE CHEMICAL BIOLOGY
Volume 9, Issue 2, Pages 126-133

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/NCHEMBIO.1156

Keywords

-

Funding

  1. Hjarnfonden
  2. European Union
  3. Swedish Foundation for Strategic Research
  4. Karolinska Institutet
  5. Karolinska Institutet (Thematic Center in Stem Cells and Regenerative Medicine)
  6. Swedish Research Council (DBRM) [2008:2811, 2011-3116, 3318]
  7. UK Research Councils Biotechnology and Biological Sciences Research Council [BB/C515771/2, BB/C511356/1, BB/I001735/1, BB/H001018/1]
  8. Swedish Medical Research Council
  9. Onassis Foundation
  10. Biotechnology and Biological Sciences Research Council [BB/I001735/1, BB/C511356/1, BB/C515771/2, BB/H001018/1] Funding Source: researchfish
  11. BBSRC [BB/H001018/1, BB/I001735/1] Funding Source: UKRI

Ask authors/readers for more resources

Liver X receptors (Lxr alpha and Lxr beta) are ligand-dependent nuclear receptors critical for ventral midbrain neurogenesis in vivo. However, no endogenous midbrain Lxr ligand has so far been identified. Here we used LC/MS and functional assays to identify cholic acid as a new Lxr ligand. Moreover, 24(S),25-epoxycholesterol (24,25-EC) was found to be the most potent and abundant Lxr ligand in the developing mouse midbrain. Both Lxr ligands promoted neural development in an Lxr-dependent manner in zebrafish in vivo. Notably, each ligand selectively regulated the development of distinct midbrain neuronal populations. Whereas cholic acid increased survival and neurogenesis of Brn3a-positive red nucleus neurons, 24,25-EC promoted dopaminergic neurogenesis. These results identify an entirely new class of highly selective and cell type-specific regulators of neurogenesis and neuronal survival. Moreover, 24,25-EC promoted dopaminergic differentiation of embryonic stem cells, suggesting that Lxr ligands may thus contribute to the development of cell replacement and regenerative therapies for Parkinson's disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available